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Abstract
Background and Purpose—Elevated plasma homocysteine levels are associated with stroke.
However, this might be a reflection of bias or confounding because trials have failed to demonstrate an
effect from homocysteine lowering in stroke patients, although a possible benefit has been suggested in
lacunar stroke. Genetic studies could potentially overcome these issues because genetic variants are
inherited randomly and are fixed at conception. Therefore, we tested the homocysteine levels–
associated genetic variant MTHFR C677T for association with magnetic resonance imaging–confirmed
lacunar stroke and compared this with associations with large artery and cardioembolic stroke subtypes.
Methods—We included 1359 magnetic resonance imaging–confirmed lacunar stroke cases, 1824 large
artery stroke cases, 1970 cardioembolic stroke cases, and 14 448 controls, all of European ancestry.
Furthermore, we studied 3670 ischemic stroke patients in whom white matter hyperintensities volume
was measured. We tested MTHFR C677T for association with stroke subtypes and white matter
hyperintensities volume. Because of the established association of homocysteine with hypertension, we
additionally stratified for hypertension status.
Results—MTHFR C677T was associated with lacunar stroke (P=0.0003) and white matter
hyperintensity volume (P=0.04), but not with the other stroke subtypes. Stratifying the lacunar stroke
cases for hypertension status confirmed this association in hypertensive individuals (P=0.0002), but not
in normotensive individuals (P=0.30).
Conclusions—MTHFR C677T was associated with magnetic resonance imaging–confirmed lacunar
stroke, but not large artery or cardioembolic stroke. The association may act through increased
susceptibility to, or interaction with, high blood pressure. This heterogeneity of association might explain
the lack of effect of lowering homocysteine in secondary prevention trials which included all strokes.
cerebral small vessel disease genetic association homocysteine hypertension
lacunar stroke MTHFR
Introduction
Elevated plasma homocysteine levels (tHcy) have been consistently associated with the risk of ischemic
stroke in observational studies.  Moreover, experimental studies suggest that increases in total
homocysteine aggravates vascular disease.  However, some clinical trials that investigated the benefit of
lowering tHcy with B vitamins to reduce the risk of stroke have been negative.  In contrast, a recent
large primary prevention trial in China, the China Stroke Primary Prevention Trial (CSPPT), which
recruited only hypertensive patients, demonstrated a beneficial effect in reducing risk of stroke.  Possible
reasons for this conflicting evidence include insufficient stroke phenotyping particularly if homocysteine is
a predominant risk factor for one type of stroke, dietary folate fortification reducing tHcy in populations in
which trials have been performed, interactions between treatment and risk factors, and insufficient
treatment duration.
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A subtype-specific effect, with elevated homocysteine primarily increasing risk for small vessel disease
(SVD) stroke, has been suggested by both epidemiological data and secondary analysis of clinical trials.
Case–control studies have suggested that elevated homocysteine is primarily a risk factor for lacunar
stroke  and that there may be heterogeneity even within this subtype, with strongest associations in
those SVD cases with multiple lacunar infarcts and confluent leukoaraiosis on magnetic resonance
imaging (MRI).  Most previous clinical trials that investigated the benefit of lowering homocysteine
studied stroke as a combined event lumping together all different etiologies (ie, hemorrhage and
ischemic and ischemic stroke subtypes). A secondary analysis in the Vitamins to Prevent Stroke
(VITATOPS) trial  found a borderline treatment effect in patients with lacunar stroke (hazard ratio 0.80
(95% confidence interval [CI] 0.67–0.96)), whereas an MRI VITATOPS substudy found vitamin-lowering
therapy was associated with reduced white matter lesion volume progression in patients with severe
white matter lesions.  A further possibility is that elevated homocysteine may interact with certain
cardiovascular risk factors, and treatment effect may only be detected if these interactions are taken into
account; of possible relevance, the positive CSPPT trial was only performed in hypertensive individuals.
Another possible explanation for the conflicting epidemiological and clinical trial data is that the
association between homocysteine and risk of ischemic stroke is a reflection of reverse causality or
residual confounding, that is, elevated tHcy does not play a causal role in stroke pathogenesis but are
merely noncausally associated with an increased risk of stroke. Genetic studies have the potential to
overcome these issues by using genetic variants associated with elevated tHcy as a proxy for tHcy
because the inheritance of genetic variants is random and not influenced by confounding factors. The
most often studied genetic variant, showing the strongest association with increased tHcy, is the cytosine
(C) to thymine (T) substitution at position 677 of the methylene tetrahydrofolate reductase (MTHFR)
gene (rs1801133).  Case–control studies that investigated the association of the MTHFR C677T
variant with stroke yielded inconsistent results, which is likely because of small sample sizes and the
varying stroke phenotypes studied. Meta-analyses have produced conflicting results with an association
reported between MTHFR and ischemic heart disease and stroke in one study but not with stroke in
another.  Studies using detailed MRI-based stroke phenotyping have suggested the association may
be confined to, or strongest in, patients with the lacunar stroke subtype.
Based on the above data, we hypothesised that the MTHFR C677T variant may be a specific risk factor
for SVD but not for other stroke subtypes. Lacunar infarcts are small and frequently not seen on
computed tomography, and therefore, MRI is important for accurate diagnosis.  Therefore, we
determined whether the MTHFR polymorphism is associated with MRI-confirmed lacunar stroke. We
compared these results with similar analyses from patients with cardioembolic and large artery stroke. In
addition, we determined whether the same polymorphism was associated with MRI white matter
hyperintensities, another marker of SVD. Because of the known association of hypertension with both
tHcy and stroke, and in view of the positive results from the recent CSPPT study, we also stratified the
analyses by hypertension status.
Methods
Stroke Populations
We included 1359 MRI-defined lacunar stroke cases from the UK young lacunar stroke DNA study, the
Leuven Stroke Study (LSS), and the MRI-confirmed lacunar stroke collaboration (MCLSC), including
cohorts from the UK, Germany, Italy, and Australia (Table I in the online-only Data Supplement). Lacunar
stroke was defined as a clinical lacunar syndrome  with an anatomically corresponding lacunar infarct
on MRI (subcortical infarct ≤15 mm in diameter). All MRI scans were centrally reviewed by one physician
(H.S. Markus). Exclusion criteria were stenosis >50% in the extra- or intracranial cerebral vessels;
cardioembolic source of stroke, defined according to the Trial of Organization 10172 in Acute Stroke
Treatment (TOAST) criteria  as high or moderate probability; subcortical infarct >15 mm in diameter, as
these can be caused by embolic mechanisms (striatocapsular infarcts); any other specific cause of
stroke (eg, lupus anticoagulant, cerebral vasculitis, dissection, monogenic forms of stroke, eg, cerebral
autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]). Large-
artery and cardioembolic stroke cases were obtained from Genetic Risk Factors for Leukoaraiosis Study
(GENESIS), LSS, MCLSC, and the Wellcome Trust Case Control Immunochip Consortium (WTCCC2-
Immunochip), including cohorts from the UK, Germany, Belgium, Italy, Sweden, Poland, Austria, and
Australia. Cases were classified into stroke subtypes according to the pathophysiological TOAST
classification,  using clinical assessment, as well as brain and vascular imaging where available.
Hypertension was defined as prescription of antihypertensives before stroke or systolic blood pressure
>140 mm Hg or diastolic blood pressure >90 mm Hg >1 week post stroke. Fourteen thousand four
hundred and forty-eight ancestry-matched controls were obtained from the same geographical location
as the cases in each group. A description and characteristics of all cohorts are given in Table I in the
online-only Data Supplement.
White Matter Hyperintensity Volumes Population
The white matter hyperintensity (WMH) volume population (n=3670) was derived from the International
Stroke Genetics Consortium (ISGC) WMH collaboration. This collaboration measured WMH volumes in
patients with ischemic stroke from the UK, Italy, Belgium, Germany, Australia, and USA (Table II in the
online-only Data Supplement). Inclusion criteria were >18 years of age, self-reported European ancestry,
and a diagnosis of ischemic stroke. Exclusion criteria were any other cause of white matter disease,
including CADASIL, vasculitis, and demyelinating and mitochondrial disorders. MRI scans were acquired
as part of routine clinical practice for evaluation of ischemic stroke. Fluid-attenuated inversion recovery
sequences were primarily used for leukoaraiosis analysis; however, in their absence, T2 sequences
were used. All scans were quantitatively graded to obtain a WMH volume, which was normalized for
intracranial volume. WMH volume was measured in the hemisphere contralateral to the infarct and
doubled to obtain whole brain volumes. Patients with bilateral nonlacunar infarcts were excluded. All
neuroimaging analyses have been previously described.
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Genotyping
Direct genotyping of rs1801133 was performed in all cohorts except WTCCC2-Immunochip using
commercially available arrays from Affymetrix or Illumina. In WTCCC2-Immunochip, rs1801133 was
imputed from the 1000 Genomes integrated variant set (March 2012) using IMPUTE v2.  The SNP was
imputed with high accuracy (imputation info score =0.91). The SNP passed genotyping frequency
thresholds (>97%) and was in Hardy–Weinberg equilibrium in all groups. To control for population
stratification, individuals were removed that did not segregate with Hapmap II European populations
based on ancestry informative principal component analysis using EIGENSTRAT software or
multidimensional scaling in PLINK software, and ancestry-informative covariates were included in all
analyses.
Statistical Analysis
In each cohort, logistic regression was performed to test for association of MTHFR C677T with MRI-
defined lacunar stroke, cardioembolic stroke, and large artery stroke, assuming an additive model and
adjusting for ancestry-informative principal components.
For each cohort, the association between WMH volume and MTHFR C677T was determined by
performing linear regression of WMH volume on genotype dosages. Results across all cohorts were
combined using a fixed-effects inverse variance weighted meta-analysis method. Subsequently, we
repeated the analyses for MRI-defined lacunar stroke and WMH volume stratified by hypertension
status.
We set our P value threshold for the main analyses to P<0.05 and then used a Bonferroni-corrected
value (P=0.005) to assess significance in secondary analyses.
Results
Stroke Analyses
MTHFR C677T was significantly associated with lacunar stroke (odds ratio [OR] 1.20, 95% CI 1.09–
1.33; P=0.0003), but not with large-artery stroke (OR 1.01, 95% CI 0.93–1.08; P=0.88) or cardioembolic
stroke (OR 1.03, 95% CI 0.96–1.11; P=0.44; Figure 1).
Download figure  Open in new tab  Download powerpoint
Figure 1.
Forest plot for the association of MTHFR C677T with stroke subtypes. The size of the box is
inversely proportional to the estimate variance of the effect estimator. GENESIS indicates Genetic
Risk Factors for Leukoaraiosis Study; LSS, Leuven Stroke Study; MCLSC, magnetic resonance
imaging–confirmed lacunar stroke collaboration; and WTCCC2-Immunochip, Wellcome Trust Case
Control Immunochip Consortium.
In the lacunar stroke cases, the association was most pronounced in homozygotes (OR 1.48, 95% CI
1.20–1.84 for TT versus CC; P=0.0003 and OR 1.17, 95% CI 1.01–1.36 for CT versus CC; P=0.03).
The overall prevalence of hypertension in the lacunar stroke cases was 72.6%. There were no
differences in the prevalence of hypertension according to MTHFR genotype (72.0% in CC, 73.4% in CT,
and 71.2% in TT). Stratifying the lacunar stroke cases for hypertension status demonstrated the
association of MTHFR C677T with lacunar stroke was present in hypertensives (OR 1.24, 95% CI 1.11–
1.38; P=0.0002), but not in normotensives (OR 1.09, 95% CI 0.92–1.29; P=0.30). In hypertensive and
normotensive cases separately, the association of MTHFR C677T with lacunar stroke was again most
pronounced in homozygotes (Table).
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Table.
Association Between MTHFR C677T Genotypes and MRI-Defined Lacunar Stroke
WMH Volumes Analyses
MTHFR C677T was significantly associated with WMH volume (OR 1.06, 95% CI 1.01–1.11; P=0.04;
Figure 2). In the secondary analyses in which we stratified by hypertension status, there was a
borderline association for either hypertensive cases (OR 1.06, 95% CI 1.00–1.13; P=0.05), although this
did not pass the Bonferroni-corrected threshold, whereas there was no association in normotensive
cases (OR 1.02, 95% CI 0.95–1.11; P=0.57).
Download figure  Open in new tab  Download powerpoint
Figure 2.
Forest plot for the association of MTHFR C677T with WMH. The size of the box is inversely
proportional to the estimate variance of the effect estimator. ASGC indicates Australian Stroke
Genetics Collaborative; GENESIS, Genetic Risk Factors for Leukoaraiosis Study; ISGS, Ischemic
Stroke Genetics Study; LSS, Leuven Stroke Study; MGH, Massachusetts General Hospital; SGUL,
St Georges University of London; SWISS, Sibling with Ischemic Stroke Study; and WTCCC2,
Wellcome Trust Case-Control Consortium 2.
Discussion
In the present study, we showed that the tHcy-associated genetic variant MTHFR C677T was associated
with lacunar stroke risk and cerebral SVD, but not for large artery or cardioembolic stroke, and that this
association was restricted to patients with hypertension. Thereby, this study supports the hypothesis that
homocysteine is a risk factor for specifically SVD and not for the other stroke subtypes.
Previous genetic association studies linking homocysteine to ischemic stroke have produced conflicting
results.  Such candidate studies may be influenced by publication bias, which is reduced in large
multicentre GWAS studies. A recent analysis of 18 SNPs associated with tHcy reported equivocal results
in 12 389 ischemic stroke cases (METASTROKE).  There was no association between any SNPs
associated with tHcy and all ischemic stroke or large artery or cardioembolic subtypes, consistent with
this study. However, one SNP was associated with lacunar stroke (rs9369898, MUT), but no association
was found with the MTHFR polymorphism.
Our study is the first large-scale study to include MRI-based phenotyping of lacunar stroke. The majority
of stroke cases in previous studies have relied on CT brain imaging in combination of a diagnosis of a
lacunar stroke syndrome. In ≤50% of cases, a clinical lacunar syndrome is caused by pathologies other
than SVD.
Another possible reason for the conflicting results between different studies is dietary folic acid
fortification in certain populations. This was present in some cohorts in METASTROKE and might have
attenuated any association with MTHFR C677T in METASTROKE.  In the present study, folic acid
fortification was not used in any of the included stroke cohorts, but was used in some of the included
WMH volume cohorts. The association shown between MTHFR C677T and WMH volume in the present
study might have been attenuated by the inclusion of these folic acid–fortified cohorts.
The SVD-specific effect of MTHFR C677T in the present study might reflect the effects of increased tHcy
in SVD patients with this genetic variant. Although we did not assess tHcy in the present study and,
therefore, cannot draw conclusions on this association in the present study, previous studies support this
hypothesis of possible SVD-specific effect of increased tHcy. Secondary analyses of the VITATOPS trial
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suggested that homocysteine-lowering therapy may be associated with improved outcome in SVD (both
lacunar stroke and WMH) but not in other stroke subtypes.  In the VITATOPS trial, in which lacunar
stroke subtyping was largely based on a clinical stroke syndrome with computed tomography imaging, a
borderline significant reduction in recurrent stroke occurred in patients with SVD; based on our results,
one could hypothesise that this treatment effect might be stronger in MRI-confirmed lacunar stroke.
Consistent with this specific effect in SVD are the results of an MRI substudy in 359 individuals from
VITATOPS; although no association was found in the group as a whole, in a subanalysis of patients with
MRI evidence of severe SVD at baseline, B vitamin supplementation was associated with a significant
reduction in WMH volume change.  Two meta-analyses on previous genetic association studies linking
MTHFR with WMH on MRI could not confirm an association between MTHFR and WMH.  Individual
studies that were included in these meta-analyses had only small number of patients, and it was
suggested that much larger studies would be needed to detect an association.  In the present study, we
included twice as many subjects as the largest study in the previous meta-analyses that assessed WMH
on a dichotomous scale and three times as many subjects as the study that assessed WMH volume.
We found that the association of MTHFR C677T with lacunar stroke was restricted to hypertensive
individuals. One possible explanation for this finding exclusively in hypertensive individuals might be that
the association acts through increased susceptibility to, or interaction with, high blood pressure.
Interestingly, the recent large primary prevention CSPPT trial showed a benefit of homocysteine-lowering
therapy in reducing stroke risk in hypertensive individuals from a population in which folic acid
fortification was not occurring.
The major strength of our study is the confirmation of all lacunar strokes by MRI and the relatively large
sample size. Furthermore, the approach of using a genetic proxy for tHcy reduces the likeliness of
reversed causality and residual confounding compared with previous observational studies. The
relationship between tHcy and stroke in observational studies might be confounded by unmeasured or
not adequately measured factors (eg, other dietary factors) that are causally associated with stroke. In
contrast, genetic studies rely on the fact that genetic variants are fixed from conception and are not
influenced by other traits.
Moreover, the stroke cohorts were derived from countries in which folic acid fortification was not
implemented at the time of stroke, which maximized the chances of demonstrating an effect for MTHFR
C677T. We also included an analysis of WMH volume in ischemic stroke patients. Stroke patients
represent an enriched population in whom WMH are increased. It has been shown, however, that the
genetic factors underlying WMH in ischemic stroke patients seem to be similar to those in population-
based studies of WMH.
A potential limitation of the present study is that we did not have independent replication cohorts
available to validate our findings, and therefore, future studies are warranted to confirm these interesting
findings. Furthermore, although MTHFR C677T is strongly associated with tHcy in other studies,  we
could not also directly assess the association of tHcy with stroke subtype in the present study because
tHcy measurements were not available in all of our cohorts.
In summary, we showed that MTHFR C677T was associated with lacunar stroke in hypertensive
individuals, supporting a possible causal role for homocysteine in the pathogenesis of cerebral SVD. Our
results suggest that any future trials investigating the benefit of lowering homocysteine in stroke patients
should focus on the SVD subtype and that they should incorporate MRI-based diagnosis.
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